W. Perkins et al., A MULTICENTER 12-WEEK OPEN STUDY OF A LIPID-SOLUBLE FOLATE ANTAGONIST, PIRITREXIM IN SEVERE PSORIASIS, British journal of dermatology, 129(5), 1993, pp. 584-589
An open, 12-week, multicentre study was conducted to assess the effica
cy of piritrexim isethionate in the treatment of severe psoriasis. Pir
itrexim isethionate is a lipid-soluble dihydrofolate reductase inhibit
or which cannot form polyglutamates, and may be as effective as methot
rexate in the treatment of psoriasis. If, as is suspected, but as yet
unproven, methotrexate polyglutamates are responsible for the hepatoto
xicity of methotrexate, piritrexim should be less hepatotoxic, and may
offer an alternative to methotrexate therapy. Fifty-five patients wer
e enrolled, of whom 41 completed the study. Patients were allocated to
receive either 150, 225, 300, or 450 mg of piritrexim weekly, in divi
ded doses over 72 h (low-dose groups, 150 and 225 mg), or over 36 h (3
00 and 450 mg groups). Twenty-four of the 41 patients who completed th
e study had a greater than 50% improvement in the severity of their ps
oriasis, as demonstrated by a reduction in the Psoriasis Severity Scor
e, a measure analogous to the PASI scoring system. Adverse events were
common, but mild, and were controlled by dose reduction. Piritrexim a
ppears to be an effective therapy for severe psoriasis at doses of 300
and 450 mg weekly, in three divided doses over 36 h.